Gary M. Clark
Profile
Gary M.
Clark worked as a Director of Biostatistics & Data Processing at Cancer Therapy & Research Center Endowment, a Professor & Associate Director of Breast Center at Baylor College of Medicine, a Director at Flagship Biosciences, Inc., a Vice President of Biostatistics & Data Management at OSI Pharmaceuticals, Inc., and Array BioPharma, Inc. He also worked as an Associate Professor at the University of Kansas and a Professor at the University of Texas Health Center.
Clark received his graduate and doctorate degrees from the University of Washington.
Former positions of Gary M. Clark
| Companies | Position | End |
|---|---|---|
| Cancer Therapy & Research Center Endowment | Corporate Officer/Principal | - |
Flagship Biosciences, Inc.
 Flagship Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO. | Director/Board Member | - |
| University of Kansas | Corporate Officer/Principal | - |
| University of Texas Health Center | Corporate Officer/Principal | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
Training of Gary M. Clark
| University of Washington | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 4 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
| Cancer Therapy & Research Center Endowment | Health Services |
Flagship Biosciences, Inc.
Flagship Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO. | Commercial Services |
- Stock Market
- Insiders
- Gary M. Clark
